| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
8.08(B) |
| Last
Volume: |
2,144,916 |
Avg
Vol: |
1,949,015 |
| 52
Week Range: |
$44.82 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,762 |
108,398 |
166,494 |
290,334 |
| Total Sell Value |
$463,948 |
$6,570,910 |
$11,277,891 |
$18,676,003 |
| Total People Sold |
8 |
10 |
11 |
11 |
| Total Sell Transactions |
11 |
52 |
61 |
100 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Conroy Kevin T |
President and CEO |
• • – |
2017-11-21 |
4 |
AS |
$59.50 |
$7,976,660 |
D/D |
(134,057) |
830,052 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-11-21 |
4 |
OE |
$0.83 |
$111,267 |
D/D |
134,057 |
964,109 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-11-09 |
4 |
AS |
$58.59 |
$8,149,669 |
D/D |
(137,805) |
830,052 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-11-09 |
4 |
OE |
$0.83 |
$114,386 |
D/D |
137,815 |
967,867 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-11-01 |
4 |
AS |
$52.87 |
$2,453,768 |
D/D |
(45,775) |
239,719 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2017-10-31 |
4 |
A |
$5.95 |
$10,008 |
D/D |
1,682 |
37,558 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-10-02 |
4 |
AS |
$47.16 |
$3,820,734 |
D/D |
(81,025) |
285,494 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-10-02 |
4 |
OE |
$13.96 |
$492,090 |
D/D |
35,250 |
366,519 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2017-10-02 |
4 |
AS |
$47.15 |
$1,373,115 |
D/D |
(29,115) |
35,876 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2017-09-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,688 |
64,991 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-09-06 |
4 |
OE |
$9.07 |
$399,989 |
D/D |
42,317 |
331,269 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-09-05 |
4 |
AS |
$40.80 |
$3,088,801 |
D/D |
(75,683) |
288,952 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-09-05 |
4 |
OE |
$5.70 |
$868,356 |
D/D |
75,683 |
364,635 |
|
- |
|
| Thompson David |
Director |
– • – |
2017-08-28 |
4 |
OE |
$3.43 |
$318,121 |
D/D |
52,472 |
196,444 |
|
- |
|
| Carey Thomas D. |
Director |
– • – |
2017-08-17 |
4 |
B |
$37.71 |
$94,275 |
D/D |
2,500 |
60,858 |
2.39 |
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-08-17 |
4 |
OE |
$10.82 |
$99,998 |
D/D |
9,242 |
830,052 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2017-07-31 |
4 |
AS |
$39.41 |
$230,391 |
D/D |
(5,846) |
14,015 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2017-07-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,750 |
19,861 |
|
- |
|
| Fallon John A. |
Director |
– • – |
2017-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
5,273 |
32,910 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2017-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
791 |
18,376 |
|
- |
|
| Levangie Daniel J |
Director |
– • – |
2017-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
7,119 |
73,597 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2017-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
7,119 |
113,046 |
|
- |
|
| Sterling Lionel |
Director |
– • – |
2017-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,328 |
127,575 |
|
- |
|
| Thompson David |
Director |
– • – |
2017-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
7,593 |
143,972 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2017-07-27 |
4 |
A |
$0.00 |
$0 |
D/D |
5,273 |
38,279 |
|
- |
|
777 Records found
|
|
Page 23 of 32 |
|
|
0.20 (0.44%) 
